A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection
← catalyst calendarNCT07762027 · readout ≤ 315 d
Sponsored by Assembly Biosciences (industry) · ASMB — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
80estimated
Sites
22
Countries
France, Georgia, Germany +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Oct 2026 | estimated | When the study began enrolling |
| Primary completion | Jun 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Hepatitis D Infection
Interventions
- Drug: ABI-6250
- Drug: ABI-6250
Primary outcomes
what the primary-completion date above is the date OFProportion of subjects with adverse events (AEs), premature treatment discontinuation and abnormal laboratory results.
measured Through study completion, an average of 1.5 years.
Evaluating the change from baseline in HDV RNA & ALT levels
measured Through study completion, an average of 1.5 years.
Permalink · ASMB's whole pipeline · Catalyst calendar · Every registered study · What changed